The Valley Desk

LetterBlood cancer journalPublished

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names GSK. Affiliation source

Institution
GSK

Publication record

Type
Letter
Venue
Blood cancer journal
Published
PubMed ID
42892628
PubMed Central ID
PMC13676618
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal